Advani RH, Flinn I, Popplewell L, et al. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. J Clin Oncol 36, 2018 (suppl; abstr 7504)
Pleidooi voor klinische implementatie van PSMA PET/CT in verschillende fasen prostaatkanker
mei 2024 | Uro-oncologie